Pigmentation Disorders Treatment Market Size, Share & Trends Analysis Report By Types of Disorder (Albinism, Vitiligo, Melasma, Post-inflammatory Hyperpigmentation (PIH), Other Types of Disorders), By Treatment Type (Topical Treatment, Dermabrasion, Chemical Peels, Laser Treatment, Phototherapy, Other Treatment Types) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2022-2030

Market Overview

The global pigmentation disorders treatment market size was valued at USD 6,560.60 million in 2021. It is projected to reach USD 12,369.18 million by 2030, growing at a CAGR of 7.30% during the forecast period (2022-2030). 

The rising frequency of pigmentation disorders and rising spending on dermatological treatments are two factors that have contributed to the expansion of the global market for pigmentation disorders therapy. Some common pigmentation disorders are post-inflammatory hyperpigmentation, melasma, solar lentigines, ephelides (freckles), vitiligo, and café au lait macules. Despite being largely benign, some illnesses can be upsetting for patients. Melanoma and its precursors can be ruled out using a skin biopsy, skin examination, and a thorough dermatologic history. Pigmentation diseases are treated with topical medicines, chemical peels, cryotherapy, light or laser therapy, or a combination of these techniques to address the underlying illness.

Market Dynamics

Global pigmentation disorders treatment market drivers

Rising cases of pigmentation disorders

The aging global population, the rising upgrade in lifestyle, and the rising desire for skin lightening are the primary factors anticipated to drive the global pigmentation disorders treatment market. There are between 65 and 95 million cases of vitiligo worldwide, according to the most recent estimates from the Vitiligo Research Foundation. Due to the lack of research into vitiligo, the actual number may be far higher.

The prevalence of vitiligo varies locally from 0.004% to 9.98%, depending on the location and age group, while the global average is between 0.5% and 2% of the population. Thus, the market is anticipated to have considerable growth during the forecast period due to the rising frequency of pigmentation disorders and the growing global geriatric population.

Global pigmentation disorders treatment market restraint

Very expensive cosmetical procedure

The high cost of cosmetic operations is anticipated to slow industry expansion globally. According to a research article written in 2020 and published in Walk-in Dermatology, a dermatologist's initial consultation in the United States typically costs around USD 150. The cost of dermatological therapy will also increase as a result of follow-up appointments, different therapies, and numerous procedures done during a dermatology consultation. The cost of skin treatment with combination lasers was USD 383, according to the Aesthetic Plastic Surgery National Databank, Statistics 2020.

In the United States, incorporating chemical peel cost about USD 196 in 2020. Additionally, this cost would increase because each treatment would need many sessions, which would increase the cost of the process. In addition, the Vitiligo Research Foundation reports that the price of a potent topical corticosteroid such as clobetasol propionate can range from USD 20 to USD 300 or more.

Global pigmentation disorders treatment market opportunities

Rising disposable incomes and favorable consumer conditions

The cost of dermatological treatments is rising as a result of greater global population awareness of various dermatological issues, which is further associated with rising living standards and per capita income levels across all countries. India's per-capita net national income reached INR 1,35,050 in 2019–20, up 6.8% from INR 1,26,406 in 2018–19, with a growth rate of 10.0%, according to annual national income and GDP 2019–20 figures given by the Ministry of Statistics and Programme Implementation. (MoSPI). Therefore, it is anticipated that increased disposable incomes and favorable consumer conditions would boost the cost of dermatological treatments, driving the market's expansion over the projection period.

Regional Analysis

The global pigmentation disorders treatment market is bifurcated into four regions, namely North America, Europe, Asia-Pacific, and LAMEA. 

North america dominates the global market

North America is the most significant shareholder in the global pigmentation disorders treatment market and is expected to grow at a CAGR of 7.30% during the forecast period. Due to the rising prevalence of pigmentation disorders, the accessibility of cutting-edge healthcare services, the presence of key market players, and the rising cost of treatment options, the United States is predicted to experience growth in the overall market for the treatment of pigmentation disorders over the forecast period. There may be a sharp rise in demand for treatment alternatives for pigmentation disorders due to increased research and development costs and the existence of significant companies.

Europe is expected to grow at a CAGR of 7.50%, generating USD 3,054.35 million during the forecast period. Due to the rising frequency of pigmentation diseases, sizable clinics offering cutting-edge care, and numerous companies, the market for treating pigmentation disorders is expanding in Germany. The nation also has many healthcare-related businesses and sizable government funding and awareness-raising initiatives. The market under study is expanding rapidly because the United Kingdom has a well-established healthcare system and a sizable business population. The market is becoming more lucrative as a result of the availability of cutting-edge medical technologies and a vast array of items.

Asia-Pacific is anticipated to grow significantly during the forecast period. The population of Japan is likewise aging more quickly than any other country. By 2060, the 65 and older age group is expected to make up 40% of the population, according to the Health and Welfare Ministry. Therefore, as the senior population grows, so do skin diseases, which raises the need for solutions to address pigmentation disorders. Over 20 genes are responsible for Oculocutaneous Albinism (OCA), according to an article titled "Current landscape of Oculocutaneous Albinism in Japan," published in 2020. OCA4 is the most prevalent subtype in Japanese, followed by OCA1, HPS1, and OCA2. Additionally, growing consumer awareness of aesthetic procedures and increased uptake of technologically sophisticated devices like microdermabrasion fuel market expansion.

Saudi Arabia, Qatar, Oman, Kuwait, Bahrain, the United Arab Emirates, and Saudi Arabia are studied in the LAMEA. The GCC nations share social and economic backgrounds, health problems, and nearly identical health systems and regulations. According to a five-year retrospective study of skin diseases reported by Fawwaz al. shammrie et al., published in the Journal of Dermatology and Dermatological Surgery, 2017, in Saudi Arabia, viral wart (7%), psoriasis (4%), leishmania (4%), Tinea (2%), other pilosebaceous (1%), and others (3%) are the most prevalent skin-related conditions. Alopecia (8%), other pigmentary (7%), and Israel, Egypt, Iran, Syria, Jordan, Lebanon, Nigeria, and other countries are included in the rest of the Middle East and Africa. In particular, it is projected that this region will require a few more years to witness a firmly established market for novel therapies like phototherapy, laser therapy, and microdermabrasion equipment.

Segmental Analysis

The global pigmentation disorders treatment market is segmented by type of disorder and treatment.

By type of disorder analysis

Based on the type of disorder, the global market is bifurcated into albinism, vitiligo, melasma, post-inflammatory hyperpigmentation (PIH), and other types of disorders.

The melasma segment owns the highest market share and is expected to grow at a CAGR of 7.60% during the forecast period. Melasma produces an excessive amount of melanin, a pigment that naturally gives skin, hair, and eyes their color. This common skin disorder manifests as brown to gray-brown areas of skin. Melasma typically develops on the face, although it can also appear on the neck and forearms. Females with darker skin types are most frequently affected by the acquired hyperpigmentation disorder known as melasma. Many factors, including sun exposure, genetic predispositions, and female sex hormones, contribute to it. Melasma formation is influenced by increased melanogenesis, extracellular matrix changes, inflammation, and angiogenesis.

Melanin, a pigment that ordinarily imparts color to the skin, hair, and eyes, is diminished or absent in people with albinism (a hereditary disorder). Depending on the genetic source of the disorder, different kinds of albinism may inherit in different ways. Ocular albinism (OA) is far less frequent and predominantly affects the eyes, while oculocutaneous albinism (OCA) affects the eyes, hair, and skin. Skin and hair may appear similar or slightly lighter than other family members. People with albinism make up between one in every 17,000 and 20,000 people in the populations of North America and Europe.

By treatment analysis

Based on the treatment, the global market is bifurcated into topical treatment, dermabrasion, chemical peels, laser treatment, phototherapy, and other treatment types.

The topical treatment segment is the highest contributor to the market and is expected to grow at a CAGR of 7.55% during the forecast period. Topical treatment entails applying creams, lotions, ointments, and serums topically to treat various pigmentation conditions. These products are made with a variety of active components. Hydroquinone, corticosteroids, retinoids, and Kojic acid are a few of the active substances. There are some evidences that retinoids like tazarotene (0.1% cream), tretinoin (0.025% to 0.05%), and adapalene gel (Differin, 0.1% or 0.3%) may lessen hyperpigmentation. The US Food and Drug Administration has authorized the over-the-counter sale of adapalene 0.1% gel. The use of topical corticosteroids (TC) is considered to be one of the most successful therapeutic techniques for pigmentation problems. Common corticosteroids include fluticasone propionate, betamethasone valerate, and hydrocortisone butyrate.

Dermabrasion is a popular cosmetic operation performed worldwide since it is a quick, simple, safe procedure with good results and no downtime. The practice of dermabrasion aids in removing the topmost layer of dry, dead skin cells. The top layer of the skin is removed and leveled during dermabrasion using a wire brush or a diamond wheel with rough edges. As the treated region heals, fresh skin can eventually replace the old. Melasma can be treated using dermabrasion, a cosmetic procedure that is secure and efficient. Microdermabrasion is considered an efficient treatment for melasma when combined with topical and oral medication. The fact that combination therapy targets a variety of underlying reasons makes it an effective treatment for melasma.

Recent Developments

• July 2022- Opzelura (ruxolitinib) cream was approved by the US Food and Drug Administration to treat nonsegmental vitiligo in adult and pediatric patients 12 years and older.
• June 2022- A collaboration agreement was struck by Ahammune Biosciences Private Limited and Veeda Clinical Research Limited of India for the human trials of AB1001, an investigational new drug being developed by Ahammune as a topical therapy for vitiligo.